This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Here's How to Play Novo Nordisk (NVO) After Q2 Earnings Miss
by Ahan Chakraborty
Novo Nordisk (NVO) is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs. New investors should utilize the existing opportunity to make an entry.
PFENegative Net Change NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results
by Zacks Equity Research
Exelixis' (EXEL) shares rally following an impressive performance in the second quarter, buoyed by a surge in license revenues.
BMYPositive Net Change EXELPositive Net Change KRYSNegative Net Change TRDAPositive Net Change
biotechnology biotechs pharmaceuticals
The Zacks Analyst Blog Highlights Nomura Research Institute, Manhattan Associates and Exact Sciences
by Zacks Equity Research
Nomura Research Institute, Manhattan Associates and Exact Sciences are part of the Zacks top Analyst Blog.
MANHNegative Net Change EXASNegative Net Change NRILYNegative Net Change
biotechnology business-services computers
Bristol Myers (BMY) Gains 16% in a Month: Should You Buy or Wait?
by Ekta Bagri
Bristol Myers' (BMY) impressive second-quarter results propelled the stock in the past month. However, we advise investors not to be over-optimistic at this point and look before they leap.
BMYPositive Net Change PFENegative Net Change GILDPositive Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid
by Zacks Equity Research
Pacira (PCRX) falls 48% as the District Court of New Jersey rules that the company's '495 patent for its lead drug, Exparel, is not valid.
PCRXPositive Net Change FULCPositive Net Change IMTXNegative Net Change TRDAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated
by Zacks Equity Research
Amicus (FOLD) rises 13% as it reports second-quarter 2024 results, wherein both earnings and sales beat the Zacks Consensus Estimate. The company updates its financial guidance for 2024.
FOLDNegative Net Change ANIXNo Net Change AKROPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pre-Markets in Red to Close an Eventful Week, Earnings Mixed
by Zacks Equity Research
Pre-Markets in Red to Close an Eventful Week, Earnings Mixed.
BAPositive Net Change SATSNegative Net Change EVRGNegative Net Change LEGNNegative Net Change
aerospace biotechnology communications utilities
Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Cytokinetics (CYTK) reports wider-than-expected Q2 loss as operating expenses increase. CYTK is on track to complete the rolling NDA submission for aficamten in the third quarter.
RPRXPositive Net Change CYTKNegative Net Change ANIXNo Net Change TRDAPositive Net Change
biofuels biotechnology earnings medical pharmaceuticals
Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
by Zacks Equity Research
Xenon (XENE) is down as it reports a wider-than-expected second-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
NBIXNegative Net Change XENEPositive Net Change AKROPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised
by Zacks Equity Research
Gilead (GILD) Q2 earnings and sales beat estimates on high HIV, oncology and liver disease drug sales and low expenses.
GSKNegative Net Change GILDPositive Net Change ANIXNo Net Change TRDAPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues
by Zacks Equity Research
Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY.
RHHBYNegative Net Change BMYPositive Net Change NVONegative Net Change PRTANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
ICF International (ICFI)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
ICFINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kymera (KYMR) reports a narrower-than-expected loss in the second quarter. The company expects the current cash balance to provide a runway into the first half of 2027.
SNYNegative Net Change ANIXNo Net Change KYMRNegative Net Change TRDAPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intra-Cellular (ITCI) reports second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
ITCINegative Net Change ANIXNo Net Change AKROPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Catalyst (CPRX) Rises as Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Catalyst (CPRX) gains as it reports strong second-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, primarily driven by strong Firdapse sales.
CPRXPositive Net Change ANIXNo Net Change AKROPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down
by Zacks Equity Research
Editas (EDIT) reports lower-than-expected second-quarter 2024 results as both earnings and revenues miss estimates. The stock falls 12.2%.
VRTXPositive Net Change EDITNegative Net Change AKROPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
New Strong Buy Stocks for August 8th
by Zacks Equity Research
MTH, ULS, KRYS, RCL and DRVN have been added to the Zacks Rank #1 (Strong Buy) List on August 8, 2024.
RCLNegative Net Change MTHPositive Net Change KRYSNegative Net Change DRVNPositive Net Change ULSNegative Net Change
auto-tires-trucks biotechnology business-services construction consumer-discretionary
Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel Revenues
by Zacks Equity Research
Exelixis (EXEL) beats on earnings and sales in the second quarter. Its shares are trading up in response to the results.
EXELPositive Net Change ANIXNo Net Change AKROPositive Net Change TRDAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Ameren (AEE)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
AEEPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Farmers National Banc (FMNB) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
FMNBNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues
by Zacks Equity Research
Acadia (ACAD) reports encouraging second-quarter results as both earnings and revenues beat estimates, driven by higher Nuplazid and Daybue sales.
ACADNegative Net Change ANIXNo Net Change AKROPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk (NVO) Falls as Q2 Earnings and Sales Miss, View Up
by Zacks Equity Research
Novo Nordisk (NVO) falls as it reports lower-than-expected Q2 results, missing both earnings and revenue estimates. However, sales of Diabetes and Obesity care products increase year over year.
NVONegative Net Change ANIXNo Net Change AKROPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zoetis (ZTS) Q2 Earnings & Revenues Beat, '24 Outlook Raised
by Zacks Equity Research
Zoetis (ZTS) reports better-than-expected Q2 results, beating both earnings and revenue estimates, primarily driven by strong sales of companion animal products. Management raises the 2024 outlook.
ZTSNegative Net Change ANIXNo Net Change AKROPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals vaccines
Bayer (BAYRY) Q2 Earnings In Line, Nubeqa, Kerendia Boost Sales
by Zacks Equity Research
Bayer's (BAYRY) second-quarter earnings match the consensus estimate. Sales gain from the Pharmaceutical business' strong performance.
REGNNegative Net Change JNJNegative Net Change BAYRYNegative Net Change
biotechnology earnings pharmaceuticals
Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent
by Zacks Equity Research
Regeneron's (REGN) decent second-quarter results can be attributed to strong uptake of Eylea HD sales and high Dupixent profits, even though lead drug Eylea is under pressure.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change
biotechnology biotechs earnings pharmaceuticals